表紙:体軸性脊椎関節炎 (axSpA) - 医薬品の世界市場の予測と分析
市場調査レポート
商品コード
916559

体軸性脊椎関節炎 (axSpA) - 医薬品の世界市場の予測と分析

Axial Spondyloarthritis: Global Drug Forecast and Market Analysis to 2028

出版日: | 発行: GlobalData | ページ情報: 英文 128 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.11円
体軸性脊椎関節炎 (axSpA) - 医薬品の世界市場の予測と分析
出版日: 2019年10月30日
発行: GlobalData
ページ情報: 英文 128 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

主要7ヶ国 (米国、フランス、ドイツ、イタリア、スペイン、英国、日本) における体軸性脊椎関節炎 (axSpA) の治療薬市場は、2018年の31億米ドルから、2028年までに36億米ドルまで拡大すると見られています。市場は、2018年~2028年のCAGR (複合年間成長率) で、1.5%の成長が予測されています。

当レポートでは、体軸性脊椎関節炎 (axSpA) の治療薬市場について調査分析し、疾患の概要とガイドライン、競合情勢、主要薬剤の詳細情報 (製品説明、安全性、有効性) 、SWOT分析、売上高予測、影響分析 (動向、促進要因・抑制要因) などについて、体系的な情報を提供しています。

第1章 目次

第2章 エグゼクティブサマリー

第3章 イントロダクション

第4章 疾患の概要

  • 病因・病態生理
  • 分類または病期

第5章 疫学

  • 疾患の背景
  • 危険因子と併存疾患
  • 世界・歴史的な動向
  • 予測手法
  • 疫学予測 (基本シナリオ)
  • 疫学予測 (代替シナリオ)
  • 議論

第6章 疾患の管理

  • 診断・治療の概要
  • 米国
  • EU5ヶ国
  • 日本

第7章 競合評価

  • 概要
  • バイオシミラー
  • 保険者の考察

第8章 アンメットニーズと機会の評価

  • 概要
  • 診断までの時間の改善
  • 患者は生物学的治療を拒否
  • 薬物療法の失敗への対処
  • 薬物反応のバイオマーカーを特定

第9章 パイプライン評価

  • 概要
  • 臨床開発中の有望な薬剤
  • 保険者の考察

第10章 現在・将来の企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル
    • AbbVie
    • UCB
    • Janssen Biotech
    • Eli Lilly
    • 協和キリン
    • Novartis
    • Pfizer

第11章 市場の見通し

  • 世界市場
  • 米国
  • EU5ヶ国
  • 日本

第12章 付録

図表

List of Tables

  • Table 1: Axial Spondyloarthritis: Key Metrics in the 7MM
  • Table 2: Risk Factors and Comorbidities for AS
  • Table 3: Treatment Guidelines for Axial Spondyloarthritis
  • Table 4: Country Profile - US
  • Table 5: Country Profile - 5EU
  • Table 6: Country

List of Figures

  • Figure 1: Global Sales Forecast by Country for Axial Spondyloarthritis in 2018 and 2028
  • Figure 2: Analysis of the Company Portfolio Gap in Axial Spondyloarthritis During the Forecast Period
  • Figure 3: Competitive Assessment of the Late-Stag
目次
Product Code: GDHC179PIDR

Axial spondyloarthritis (axSpA) is a disease group encompassing both ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). These conditions are chronic, autoinflammatory disorders of the sacroiliac joints and spine, an area also known as the axial skeleton. The disease is typically diagnosed in young adulthood to middle age (16-45 years) and has a seven- to nine-year delay of diagnosis. The axSpA market has historically been reliant on anti-tumor necrosis factor (TNF) therapies that have been available for over a decade, and the pipeline for drugs in late-stage development was lacking, but recent developments have led to research on novel treatment mechanisms. This will be vital in treating the underdiagnosed nr-axSpA population.

In January 2016, Novartis gained approval for Cosentyx (secukinumab), the first-in-class interleukin (IL)-17 inhibitor that was the first new biologic treatment approved for AS that was not an anti-TNF. Moreover, biosimilars of currently marketed anti-TNF biologics recently entered the market, with Remicade (infliximab) biosimilars first marketed in 2015 in Europe. This is likely to result in a highly competitive market for patients who have failed multiple non-steroidal anti-inflammatory drugs (NSAIDs). Competition will intensify with the arrival of new anti-IL-17 treatments and a new class of therapies in development, Janus kinase (JAK) inhibitors, which will offer a more convenient form of administration. With existing unmet need for all patients, particularly nr-axSpA patients, being diagnosed in a timely manner and having treatment options that are not solely subcutaneously or intravenously administered, axSpA represents an increasingly important rheumatology sector for drug developers.

GlobalData estimates that sales of drugs in the axSpA market were approximately $3.1B in 2018 in the 7MM. The US was the largest market, with approximately $2.3B in drug sales, which represented 75.3% of the total axSpA market. The 5EU market contributed $705M in sales and Japan contributed sales of $54M in 2018.

Global sales in the axSpA market are expected to grow to $3.6B by 2028, at a Compound Annual Growth Rate (CAGR) of 1.5% from 2018-2028. GlobalData forecasts the US to grow to $2.7B (74.7% of global sales), the 5EU to grow to $850M (23.9% of global sales), and Japan to shrink to $52M (1.5% of global sales) over the next 10 years.

Key Questions Answered

Over the forecast period, the axSpA market will see the entry of pipeline agents such as the interleukin 17 inhibitors and the JAK inhibitors, the sales of which will offset the loss of sales caused by the entry of biosimilars. How do products compete against each other? Which of these drugs will have the highest peak sales, and why?

Key Opinion Leaders (KOLs) interviewed by GlobalData have indicated that there are several unmet needs within the axSpA indication. What are the main unmet needs in this market? How can the pharmaceutical industry address these needs? To what degree will the therapies under development fulfill these unmet needs?

The axSpA market is likely to become a turbulent space throughout the forecast period and beyond. Which companies are set to be major players in axSpA during the forecast period?

Key Highlights

The greatest driver of growth in the global axSpA market will be the launches of five pipeline therapies during the forecast period. The entry of these anticipated therapies, including Eli Lilly's Taltz and Pfizer's tofacitinib, will be subject to moderate uptake among the AS and nr-axSpA populations.

The main barrier to growth in the axSpA market will be the patent expiry, and subsequent launch of biosimilars of Humira (adalimumab) in the US, and the genericization of tofacitinib in the latter half of the forecast across the 7MM.

The most important unmet needs in axSpA are the need for speedier diagnosis and convincing patients to start biologic therapy. The former is being addressed by the increasingly routine use of MRI instead of X-ray to diagnose patients, and the greater understanding and awareness of nr-axSpA. The latter is impacted by poor patient education about their disease and a fear of subcutaneous/intravenous injection.

Factors driving a low biologic therapy treatment rate include some negative or fearful attitudes towards subcutaneously/intravenously administered therapeutics, nr-axSpA patients not perceiving themselves as severe enough to warrant biologic treatment, and a high ACOT for some biologic therapies currently on the market and in late-stage development.

Scope

  • Overview of axSpA including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized axSpA therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2018 and forecast for ten years to 2028.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the axSpA therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global axSpA therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global axSpA therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global axSpA therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global axSpA therapeutics market from 2018-2028.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Axial Spondyloarthritis: Executive Summary

  • 2.1 Axial Spondyloarthritis Market to Experience Mild Growth from 2018-2028
  • 2.2 Late-Stage Pipeline Product Launches Will Result in New Players Establishing Themselves
  • 2.3 Persistent Unmet Needs Will Be Addressed Over the Forecast Period
  • 2.4 Interleukin Inhibitors and Janus Kinase Inhibitors Dominate the Axial Spondyloarthritis Pipeline
  • 2.5 What Do Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports
  • 3.3 Upcoming Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology
  • 4.2 Classification or Staging Systems

5 Epidemiology

  • 5.1 Disease Background
  • 5.2 Risk Factors and Comorbidities
  • 5.3 Global and Historical Trends
  • 5.4 Forecast Methodology
    • 5.4.1 Sources
    • 5.4.2 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS - Base Scenario
    • 5.4.3 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-AxSpA - Base Scenario
    • 5.4.4 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS - Alternative Scenario
    • 5.4.5 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-AxSpA - Alternative Scenario
    • 5.4.6 Forecast Assumptions and Methods, HLA-B27 Seropositivity Among Diagnosed AS Patients
  • 5.5 Epidemiological Forecast for AS and Nr-AxSpA (2018-2028) - Base Scenario
    • 5.5.1 Diagnosed Prevalent Cases of AS
    • 5.5.2 Diagnosed Prevalent Cases of Nr-AxSpA
  • 5.6 Epidemiological Forecast for AS and Nr-AxSpA (2018-2028) - Alternative Scenario
    • 5.6.1 Diagnosed Prevalent Cases of AS
    • 5.6.2 Age-Specific Diagnosed Prevalent Cases of AS
    • 5.6.3 Sex-Specific Diagnosed Prevalent Cases of AS
    • 5.6.4 Diagnosed Prevalent Cases of AS by HLA-B27 Seropositivity
    • 5.6.5 Diagnosed Prevalent Cases of Nr-AxSpA
    • 5.6.6 Age-Specific Diagnosed Prevalent Cases of Nr-AxSpA
    • 5.6.7 Sex-Specific Diagnosed Prevalent Cases of Nr-AxSpA
  • 5.7 Discussion
    • 5.7.1 Epidemiological Forecast Insight
    • 5.7.2 Limitations of the Analysis
    • 5.7.3 Strengths of the Analysis

6 Disease Management

  • 6.1 Diagnosis and Treatment Overview
  • 6.2 US
  • 6.3 5EU
  • 6.4 Japan

7 Competitive Assessment

  • 7.1 Overview
  • 7.2 Biosimilars in the Axial Spondyloarthritis Market
    • 7.2.1 Marketed Biosimilars
    • 7.2.2 Pipeline Biosimilars
  • 7.3 Payer Insight

8 Unmet Needs and Opportunity Assessment

  • 8.1 Overview
  • 8.2 Improved Time to Diagnosis
  • 8.3 Patients Refuse Biologic Treatment
  • 8.4 Addressing Drug Treatment Failure
  • 8.5 Identifying Biomarkers of Drug Response

9 Pipeline Assessment

  • 9.1 Overview
  • 9.2 Promising Drugs in Clinical Development
  • 9.3 Payer Insight

10 Current and Future Players

  • 10.1 Overview
  • 10.2 Trends in Corporate Strategy
  • 10.3 Company Profiles
    • 10.3.1 AbbVie
    • 10.3.2 UCB
    • 10.3.3 Janssen Biotech
    • 10.3.4 Eli Lilly
    • 10.3.5 Kyowa Hakko Kirin
    • 10.3.6 Novartis
    • 10.3.7 Pfizer

11 Market Outlook

  • 11.1 Global Markets
    • 11.1.1 Forecast
    • 11.1.2 Drivers and Barriers - Global Issues
  • 11.2 US
    • 11.2.1 Forecast
    • 11.2.2 Key Events
    • 11.2.3 Drivers and Barriers
  • 11.3 5EU
    • 11.3.1 Forecast
    • 11.3.2 Key Events
    • 11.3.3 Drivers and Barriers
  • 11.4 Japan
    • 11.4.1 Forecast
    • 11.4.2 Key Events
    • 11.4.3 Drivers and Barriers

12 Appendix